Myriad Genetics, Inc. (MYGN) — Financial statements
Income statement, balance sheet, and cash flow for Myriad Genetics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 825↓1.6% | 838↑11.2% | 753↑11.0% | 678↓1.8% | 691 | |
| Cost of Revenue | 248↓1.7% | 252↑6.8% | 236↑16.9% | 202↑2.2% | 198 | |
| Gross Profit | 577↓1.5% | 585↑13.2% | 517↑8.5% | 476↓3.4% | 493 | |
| Operating Expenses | ||||||
| R&D Expenses | 107↓5.8% | 113↑27.8% | 89↑3.9% | 85↑4.3% | 82 | |
| General & Administrative Expenses | 257↓6.9% | 276↓2.7% | 284↑14.4% | 248↓53.9% | 538 | |
| Selling & Marketing Expenses | 281↓1.2% | 284↓1.8% | 289↑8.4% | 267 | 0.00 | |
| SG&A Expenses | 538↓4.0% | 560↓2.3% | 573↑11.3% | 515↓4.3% | 538 | |
| Other Expenses | 0.00↓100.0% | 36↓68.5% | 113↑567.5% | 17↓73.5% | 64 | |
| Operating Expenses | 644↓9.1% | 709↓8.5% | 774↑25.5% | 617↓9.7% | 684 | |
| Total Costs & Expenses | 892↓7.2% | 961↓4.9% | 1,011↑23.4% | 819↓7.0% | 881 | |
| Operating Results | ||||||
| Operating Income | -68↑45.1% | -124↑52.0% | -257↓83.1% | -141↑26.2% | -191 | |
| Depreciation & Amortization | 54↓12.3% | 61↓1.1% | 62↑17.5% | 53↓16.1% | 63 | |
| EBITDA | -331↓456.1% | -60↑69.9% | -197↓133.1% | -85↓788.6% | 12 | |
| EBIT | -385↓218.6% | -121↑53.5% | -259↓88.7% | -137↓172.1% | -51 | |
| Interest & Other Income | ||||||
| Net Interest Income | -9↓690.9% | -1↓175.0% | -0.40↑33.3% | -0.60↑89.8% | -6 | |
| Interest Income | 2↑5.9% | 2↓32.0% | 3↓3.8% | 3↑271.4% | 0.70 | |
| Interest Expense | 11↑275.0% | 3↓3.4% | 3↓9.4% | 3↓51.5% | 7 | |
| Non-Operating Income | 317↑11414.3% | -3↓247.4% | 2↑159.4% | -3↑97.7% | -140 | |
| Other Income / Expenses | -327 | 0.00↑100.0% | -5 | 0.00↓100.0% | 133 | |
| Income Before Tax | -395↓219.9% | -124↑52.9% | -262↓86.5% | -141↓146.2% | -57 | |
| Income Tax Expense | -29↓868.4% | 4↑245.5% | 1↑103.8% | -29↑4.3% | -30 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -366↓187.4% | -127↑51.7% | -263↓135.1% | -112↓311.8% | -27 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -366↓187.4% | -127↑51.7% | -263↓135.1% | -112↓311.8% | -27 | |
| Bottom-Line Net Income | -366↓187.4% | -127↑51.7% | -263↓135.1% | -112↓311.8% | -27 | |
| EPS (Basic) | -3.96↓180.9% | -1.41↑55.7% | -3.18↓128.8% | -1.39↓297.1% | -0.35 | |
| EPS (Diluted) | -3.96↓180.9% | -1.41↑55.7% | -3.18↓128.8% | -1.39↓297.1% | -0.35 | |
| Weighted Average Shares | 93↑3.0% | 91↑9.4% | 83↑2.8% | 81↑3.7% | 78 | |
| Weighted Average Diluted Shares | 93↑3.0% | 91↑9.4% | 83↑2.7% | 81↑3.3% | 78 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.